Eleonora Canale

Eleonora Canale

Auto-generated profile, based on publicly available information

Eleonora Canale

Department of Surgery and Cancer, Imperial College London, London, United Kingdom. 2

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Cancer Discovery
Verified
Journal Article
Open access
DRDalia Rosano
Dalia Rosano
ESEmre Sofyali
Emre Sofyali
HDHeena Dhiman
Heena Dhiman
CGChiara Ghirardi
Chiara Ghirardi
DIDiana Ivanoiu
Diana Ivanoiu
LMLuca Magnani
Luca Magnani
Patients with estrogen receptor–positive breast cancer receive adjuvant endocrine therapies (ET) that delay relapse by targeting clinically undetectable micrometastatic deposits. Yet, up to 50% of patients relapse even decades after surgery through unknown mechanisms likely involving dormancy. To investigate genetic and transcriptional changes underlying tumor awakening, we analyzed late relapse patients and longitudinally profiled a rare cohort treated with long-term neoadjuvant ETs until progression. Next, we developed an in vitro evolutionary study to record the adaptive strategies of individual lineages in unperturbed parallel experiments. Our data demonstrate that ETs induce nongenetic cell state transitions into dormancy in a stochastic subset of cells via epigenetic reprogramming. Single lineages with divergent phenotypes awaken unpredictably in the absence of recurrent genetic alterations. Targeting the dormant epigenome shows promising activity against adapting cancer cells. Overall, this study uncovers the contribution of epigenetic adaptation to the evolution of resistance to ETs. Significance: This study advances the understanding of therapy-induced dormancy with potential clinical implications for breast cancer. Estrogen receptor-positive breast cancer cells adapt to endocrine treatment by entering a dormant state characterized by strong heterochromatinization with no recurrent genetic changes. Targeting the epigenetic rewiring impairs the adaptation of cancer cells to ETs. See related commentary by Llinas-Bertran et al., p. 704. This article is featured in Selected Articles from This Issue, p. 695

16 May 2024 in Cancer Discovery
Verified
Journal Article
Open access
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Only a handful of somatic alterations have been linked to endocrine therapy resistance in hormone-dependent breast cancer, potentially explaining ∼40% of relapses. If other mechanisms underlie the evolution of hormone-dependent breast cancer under adjuvant therapy is currently unknown. In this work, we employ functional genomics to dissect the contribution of cis-regulatory elements (CRE) to cancer evolution by focusing on 12 megabases of noncoding DNA, including clonal enhancers, gene promoters, and boundaries of topologically associating domains. Parallel epigenetic perturbation (CRISPRi) in vitro reveals context-dependent roles for many of these CREs, with a specific impact on dormancy entrance and endocrine therapy resistance. Profiling of CRE somatic alterations in a unique, longitudinal cohort of patients treated with endocrine therapies identifies a limited set of noncoding changes potentially involved in therapy resistance. Overall, our data uncover how endocrine therapies trigger the emergence of transient features which could ultimately be exploited to hinder the adaptive process. Significance: This study shows that cells adapting to endocrine therapies undergo changes in the usage or regulatory regions. Dormant cells are less vulnerable to regulatory perturbation but gain transient dependencies which can be exploited to decrease the formation of dormant persisters.

17 June 2026
Verified
Other
Open access
PDF file
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Supplementary Figure 10. SIDP identifies regulatory regions with context-dependent activity in LTED cells.

17 June 2026
Verified
Other
Open access
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Supplementary Table S19: Overlap between regions with excess of functional alterations. The regions considered in these overlaps are highlighted in table S13.1. S19.1: overlap with noncoding drivers identified by PCAWG (as listed in Supplementary Table 5 of Rheinbay et al. 2020). S19.2: overlap with regulatory mutations from breast cancer samples, as identified by HMF (as listed in Supplementary Table 5 of Dietlein et al. 2022). S19.3: overlap with noncoding mutational hotspots identified by HMF (as listed in Supplementary Table 21 of Dietlein et al. 2022). S19.4: overlap with genes associated with mutation events in non-coding regions from previous studies, as annotated by HMF (as listed in Supplementary Table 22 of Dietlein et al. 2022).

17 June 2026
Verified
Other
Open access
PDF file
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Supplementary Figure 14. TLR5 expression in ER+ cells from normal and cancer samples.

17 June 2026
Verified
Other
Open access
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Supplementary Table S6: SIDP results in T47D grown in white media (-E2) media. S6.1-3: the tables follow the same structure of S3.1-3.